For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 48,260 | |||
| General and administrative | 14,690 | |||
| Total operating expenses | 62,950 | |||
| Loss from operations | -62,950 | |||
| Interest income | 3,441 | |||
| Interest and other expense | 8 | |||
| Total other income (expense) | 3,433 | |||
| Net loss and comprehensive loss | -59,517 | |||
| Basic EPS | -4.4 | |||
| Diluted EPS | -4.4 | |||
| Basic Average Shares | 13,515,915 | |||
| Diluted Average Shares | 13,515,915 | |||
OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (OKUR)